1. Alhainen K, Sirvio J, Helkala E-L, Reinikainen K, Riekkinen P Sr. Somatostatin and cognitive functions in Alzheimer's disease—the relationship of cerebrospinal fluid somatostatin increase with clinical response to tetrahydroaminoacridine. Neurosci Lett 1991; 130:46–48.

2. Appleyard ME, Smith AD, Berman P, et al. Cholinesterase activities in cerebrospinal fluid of patients with senile dementia of Alzheimer type. Brain 1987;110:1309–1322.

3. Atack JR, Beal MF, May C, et al. Cerebrospinal fluid somatostatin and neuropeptide Y. Arch Neurol 1988;45:269–274.

4. Atack JR, May C, Kaye JA, Kay AD, Rapoport SI. Cerebrospinal fluid cholinesterases in aging and in dementia of the Alzheimer type. Ann Neurol 1988;23:161–167.

5. Basun H, Forssell LG, Wetterberg L, Winblad B. Metals and trace elements in plasma and cerebrospinal fluid in normal ageing and Alzheimer's disease. J Neural Transm 1991;4:231–258.

6. Bille A, Olafsson K, Jensen HV, Andersen J. Prolactin responses to thyrotropin-releasing hormone in multi-infarct dementia and senile dementia of the Alzheimer type. Acta Psychiatr Scand 1991; 83:321–323.

7. Blackwood DHR, Christie JE. The effects of physostigmine on memory and auditory P300 in Alzheimer-type dementia. Biol Psychiatry 1986;21:557–560.

8. Blass JP, Baker AC, Ko L. Induction of Alzheimer antigens by an uncoupler of oxidative phosphorylation. Arch Neurol 1990;47:864–869.

9. Blennow K, Davidsson P, Wallin A, et al. Differences in cerebrospinal fluid gangliosides between "probable Alzheimer's disease" and normal aging. Aging Clin Exp Res 1992;4:301–306.

10. Blennow K, Wallin A, Gottfries CG, et al. Significance of decreased lumbar CSF levels of HVA and a5-HIAA in Alzheimer's disease. Neurobiol Aging 1991;13:107–113.

11. Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry 1968;114:797–811.

12. Bracco F, Scarpa M, Rigo A, Battistin L. Determination of superoxide dismutase activity by the polarographic method of catalytic currents in the cerebrospinal fluid of aging brain and neurologic degenerative diseases. Proc Soc Exp Biol Med 1991;196:36–41.

13. Cacabelos R, Barquero M, Garcia P, Alvarez XA, Varela de Seijas E. Cerebrospinal fluid interleukin-1b (IL-1b) in Alzheimer's disease and neurological disorders. Methods Find Exp Clin Pharmacol 1991;13:455–458.

14. Chakravarti A, Slaugenhaput S, Zubenko GS. Inheritance pattern of platelet membrane fluidity in Alzheimer's disease. Am J Hum Genet 1989;44:799–805.

15. Choi-Miura N-H, Ihara Y, Fukuchi K, et al. SP-40,40 is a constituent of Alzheimer's amyloid. Acta Neuropathol 1992;83:260–264.

16. Davidson M, Davis BM, Bastiaens L, et al. Growth hormone response to edrophonium in patients with Alzheimer's disease and normal control subjects. Am J Psychiatry 1988;145:1007–1009.

17. de la Monte SM, Volicer L, Hauser SL, Wands JR. Increased levels of neuronal thread protein in cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 1992;32:733–742.

18. Degrell I, Niklasson F. Purine metabolites in the CSF in presenile and senile dementia of Alzheimer type, and in multi infarct dementia. Arch Gerontol Geriatr 1988;7:173–178.

19. Drevets WC, Rubin EH. Psychotic symptoms and the longitudinal course of senile dementia of the Alzheimer type. Biol Psychiatry 1989;25:39–48.

20. Dysken MW, Falk A, Pew B, Kuskowski M, Krahn DD. Gender differences in TRH-stimulated TSH and prolactin in primary degenerative dementia and elderly controls. Biol Psychiatry 1990; 28:144–150.

21. Eagger S, Hajimohammadreza I, Fletcher K. Platelet membrane fluidity, family history, severity and age on onset in Alzheimer's disease. Int J Geriatr Psychiatry 1990;5:395–400.

22. Elble R, Giacobini E, Scarsella GF. Cholinesterases in cerebrospinal fluid. Arch Neurol 1987;44:403–407.

23. Farlow M, Ghetti B, Benson MD, Farrow JS, van Nostrand WE, Wagner SL. Low cerebrospinal-fluid concentrations of soluble amyloid b-protein precursor in hereditary Alzheimer's disease. Lancet 1992;340:453–454.

24. Francis PT, Bowen DM, Neary D, Palo J, Wikstrom J, Olney J. Somatostatin-like immunoreactivity in lumbar cerebrospinal fluid from neurohistologically examined demented patients. Neurobiol Aging 1984;5:183–186.

25. Gomez S, Puymirat J, Valade P, Davous P, Rondot P, Cohen P. Patients with Alzheimer's disease show an increased content of 15K dalton somatostatin precursor and a lowered level of tetradecapeptide in their cerebrospinal fluid. Life Sci 1986;39:623–627.

26. Gottfries CG. Disturbance of the 5-hydroxytryptamine metabolism in brains from patients with Alzheimer's dementia. J Neural Transm 1990;30:33–43.

27. Gustafson L, Edvinsson L, Dahlgren N, et al. Intravenous physostigmine treatment of Alzheimer's disease evaluated by psychometric testing, regional cerebral blood flow (rCBF) measurement, and EEG. Psychopharmacology 1987;93:31–35.

28. Hajimohammadreza I, Brammer MJ, Eagger S. Platelet and erythrocyte membrane changes in Alzheimer's disease. Biochim Biophys Acta 1990;1025:208–214.

29. Hartikainen P, Reinikainen KJ, Soinien H, Sirvio J, Soikkeli R, Rickkinen PJ. Neurochemical markers in the cerebrospinal fluid of patients with Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis and normal controls. J Neural Transm 1992;4:53–68.

30. Hicks N, Brammer MJ, Hyumas N. Platelet membrane properties in Alzheimer and multi-infarct dementias. J Alzheimer's Dis Relat Disord 1987;1:90.

31. Holsboer F, Spengler D, Heuse RI. The role of corticotropin-releasing hormone in the pathogenesis of Cushing's disease, anorexia nervosa, alcoholism, affective disorders and dementia. Prog Brain Res 1992;93:385–417.

32. Houlihan DJ, Mulsant BH, Sweet RA, et al. A naturalistic study of trazodone in the treatment of behavioral complications of dementia. Am J Geriatr Psychiatry 1994;2:78–85.

32a Huff FJ, Mickel SF, Corkin S, Growdon JH. Cognitive functions affected by scopolamine in Alzheimer's disease and normal aging. Drug Dev Res 1988;12:271–278.

33. Janowsky DS, Risch SC. Role of acetylcholine mechanisms in the affective disorders. In: Meltzer HY, ed. Psychopharmacology: the third generation of progress. New York: Raven Press, 1987;527–533.

34. Johnson S, Domino EF. Cholinergic enzymatic activity of cerebrospinal fluid of patients with various neurologic diseases. Clin Chim Acta 1971;35:421–428.

35. Kawakatsu S, Morinobu S, Shinohara M, Totsuka S, Kobashi K. Acetylcholinesterase activities and monoamine metabolite levels in the Cerebrospinal fluid of patients with Alzheimer's disease. Biol Psychiatry 1990;28:387–400.

35a Kaye JA, May C, Daly E, Atack JR, Sweeney DJ, Luxenberg JS, Kay AD, Kaufman S, Milstien S, Friedland RP, Rapoport SI. Cerebrospinal fluid monoamine markers are decreased in dementia of the Alzheimer type with extrapyramidal features. Neurology 1988;38:554–557.

36. Kukull WA, Hinds TR, Schellenberg GD. Increased platelet membrane fluidity as a diagnostic marker for Alzheimer's disease. Neurology 1992;42:607–614.

37. Kumar V, Giacobini E. Cerebrospinal fluid choline, and acetylcholinesterase activity in familial vs. non-familial Alzheimer's disease patients. Arch Gerontol Geriatr 1988;7:111–117.

38. Lawlor BA, Sunderland T, Mellow AM, Hill JL, Molchan SE, Murphy DL. Hyperresponsivity to the serotonin agonist m-chlorophenylpiperazine in Alzheimer's disease: a controlled study. Arch Gen Psychiatry 1989;46:542–549.

39. Leake A, Charlton BG, Lowry PJ, Jackson S, Fairbairn A, Ferrier IN. Plasma N-POMC, ACTH and cortisol concentrations in a psychogeriatric population. Br J Psychiatry 1990;156:676–679.

40. Lopez OL, Boller F, Becker JT. Alzheimer's disease and depression: neuropsychological impairment and progression of the illness. Am J Psychiatry 1990;147:855–860.

41. Malm J, Kristensen B, Ekstedt J, Adolfsson R, Wester P. CSF Monoamine metabolites, cholinesterases and lactate in the adult hydrocephalus syndrome (normal pressure hydrocephalus) related to CSF hydrodynamic parameters. J Neurol Neurosurg Psychiatry 1991;54:252–259.

42. Meltzer HY, Lowy MT. The serotonin hypothesis of depression. In: Meltzer HY, ed. Psychopharmacology: the third generation of progress. New York: Raven Press, 1987;513–526.

43. Molchan SE, Hill JL, Mellow AM, Lawlor BA, Martinez R, Sunderland T. The dexamethasone suppression test in Alzheimer's disease and major depression: relationship to dementia severity, depression, and CSF monoamines. Int Psychogeriatr 1990;2:99–122.

44. Molchan SE, Lawlor BA, Hill JL, et al. CSF monoamine metabolites and somatostatin in Alzheimer's disease and major depression. Biol Psychiatry 1991;29:1110–1118.

45. Molchan SE, Lawlor BA, Hill JL, et al. The TRH stimulation test in Alzheimer's disease and major depression: relationship to clinical and CSF measures. Biol Psychiatry 1991;30:567–576.

46. Molchan SE, Manji H, Chen G, et al. Effects of chronic lithium treatment on platelet PKC isozymes in Alzheimer's and elderly control subjects. Neurosci Lett 1993;162:187–191.

47. Mulsant BH, Zubenko GS. Clinical, neuropathological, and neurochemical correlates of depression and psychosis in primary dementia. In: Emery VOB, Oxmanan TE, eds. Dementia: presentations, differential diagnosis, and nosology. Baltimore: Johns Hopkins University Press, 1994:336–352.

48. Newhouse PA, Sunderland T, Narang PK, et al. Neuroendocrine, physiologic, and behavioral responses following intravenous nicotine in nonsmoking healthy volunteers and in patients with Alzheimer's disease. Psychoneuroendocrinology 1990;15:471–484.

49. Newhouse PA, Sunderland T, Tariot PN, Mueller EA, Murphy DL, Cohen RM. Prolactin response to TRH in Alzheimer's disease and elderly controls. Biol Psychiatry 1986;21:963–967.

50. Newhouse PA, Sunderland T, Tariot PN, et al. The effects of acute scopolamine in geriatric depression. Arch Gen Psychiatry 1988; 45:906–912.

50a Oram JJ, Edwardson J, Millard PH. Investigation of cerebrospinal fluid neuropeptides in idiopathic senile dementia. Gerontology 1981;27:216–223.

51. Palmer AM, Sims NR, Bowen DM, et al. Monoamine metabolite concentrations in lumbar cerebrospinal fluid of patients with histologically verified Alzheimer's dementia. J Neurol Neurosurg Psychiatry 1984;47:481–484.

52. Palmert MR, Usiak M, Mayeux R, Raskind M, Tourtellote WW, Younkin SF. Soluble derivatives of the b amyloid protein precursor in cerebrospinal fluid: alterations in normal aging and in Alzheimer's disease. Neurology 1990;40:1028–1034.

53. Parnetti L, Gaiti A, Reboldi GP, et al. CSF Monoamine metabolites in old age dementias. Mol Chem Neuropathol 1992;16:143–157.

54. Peterson C, Goldman JE. Alterations in calcium content and biochemical processes in cultured skin fibroblasts from aged and Alzheimer donors. Proc Natl Acad Sci USA 1986;83:2758–2762.

55. Peterson C, Ratan RR, Shelanski ML. Cytosolic free calcium and cell spreading decrease in fibroblasts from aged and Alzheimer donors. Neurobiology 1986;83:7999–8001.

56. Piletz JE, Sarasua M, Whitehouse P. Intracellular membranes are more fluid in platelets of Alzheimer's disease patients. Neurobiol Aging 1991;12:401–406.

56a Pomara N, Stanley M, LeWitt PA, Galloway M, Singh R, Deptula D. Increased CSF HVA response to arecoline challenge in Alzheimer's disease. J Neural Transm 1992;90:53–65.

57. Prior R, Monning U, Schreiter-Gasser U, et al. Quantitative changes in the amyloid bA4 precursor protein in Alzheimer cerebrospinal fluid. Neurosci Lett 1991;124:69–73.

58. Raffaele KC, Berardi A, Morris PP, et al. Effects of acute infusion of the muscarinic cholinergic agonist arecoline on verbal memory and visuo-spatial function in dementia of the Alzheimer type. Prog Neuropsychopharmacol Biol Psychiatry 1991;15:643–648.

59. Raskind MA, Peskind ER, Halter JB, Jimerson DC. Norepinephrine and MHPG levels in CSF and plasma in Alzheimer's disease. Arch Gen Psychiatry 1984;41:343–346.

60. Raskind MA, Peskind ER, Veith RC, et al. Neuroendocrine responses to physostigmine in Alzheimer's disease. Arch Gen Psychiatry 1989;46:535–540.

61. Ruberg M, Villageois A, Bonnet A-M, Pillon B, Rieger F, Agid Y. Acetylcholinesterase and butyrylcholinesterase activity in the cerebrospinal fluid of patients with neurodegenerative diseases involving cholinergic systems. J Neurol Neurosurg Psychiatry 1987;50:538–543.

62. Saitoh T, Masliah E, Jin L-W, Cole GM, Wieloch T, Shapiro IP. Biology of disease: protein kinases and phosphorylation in neurologic disorders and cell death. Lab Invest 1991;65:596–616.

63. Schwartz AS, Kohlstaedt EV. Physostigmine effects in Alzheimer's disease: Relationship to dementia severity. Life Sci 1986;38:1021–1028.

64. Sunderland T, Molchan SE, Martinez RA, Vitiello B, Martin P. Drug challenge strategies in Alzheimer's disease: a focus on the scopolamine model. In: Becker RE, Giacobini E, eds. Alzheimer's disease: current research in early diagnosis. New York: Taylor & Francis, 1990;173–181.

65. Sunderland T, Rubinow DR, Tariot PN, et al. CSF somatostatin in patients with Alzheimer's disease, older depressed patients, and age-matched control subjects. Am J Psychiatry 1987;144:1313–1316.

66. Sunderland T, Tariot PN, Cohen RM, Weingartner H, Mueller EA, Murphy DL. Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls: a dose–response study. Arch Gen Psychiatry 1987;44:418–426.

67. Sunderland T, Weingartner H, Cohen RM, et al. Low-dose oral lorazepam administration in Alzheimer subjects and age-matched controls. Psychopharmacology 1989;99:129–133.

68. Sweet RA, Zubenko GS. Peripheral markers in Alzheimer's disease. In: Burns A, Levy R, eds. Dementia. London: Chapman & Hall, 1994;387–403.

69. Talamo BR, Rudel R, Kosik KS. Pathological changes in olfactory neurons in patients with Alzheimer's disease. Nature 1989; 337:736–739.

70. Tariot PN, Cohen RM, Welkowitz JA, et al. Multiple-dose arecoline infusions in Alzheimer's disease. Arch Gen Psychiatry 1988; 45:901–905.

71. Thienhaus OJ, Zemlan FP, Bienenfeld D. Growth hormone response to edrophonium in Alzheimer's disease. Am J Psychiatry 1987;144:1049–1052.

72. Tohgi H, Ueno M, Abe T, Takahashi S, Nozaki Y. Concentrations of monoamines and their metabolites in the cerebrospinal fluid from patients with senile dementia of the Alzheimer type and vascular dementia of the Binswanger type. J Neural Transm 1992;4:69–77.

73. Tsuboyama GK, Gabriel SS, Davis BM, et al. Neuroendocrine dysfunction in Alzheimer's disease: results following TRH stimulation. Biol Psychiatry 1992;32:195–198.

74. Tsuji M, Takahashi S, Akazawa S. CSF Vasopressin and cyclic nucleotide concentrations in senile dementia. Psychoneuroendocrinology 1981;6:171–176.

75. Urakami K, Takahashi K, Saito H, et al. Amyloid b protein precursors with kunitz-type inhibitor domains and acetylcholinesterase in cerebrospinal fluid from patients with dementia of the Alzheimer type. Acta Neurol Scand 1992;85:343–346.

76. Van Nostrand WE, Wagner SL, Shankle WR, et al. Decreased levels of soluble amyloid b-protein precursor in cerebrospinal fluid of live Alzheimer disease patients. Proc Natl Acad Sci USA 1992;80:2551–2555.

77. van Rensburg SJ, Carsten ME, Potocnik FCV. Membrane fluidity of platelets and erythrocytes in patients with Alzheimer's disease and the effect of small amounts of aluminum on platelet and erythrocyte membranes. Neurochem Res 1982;1:825–829.

78. Wang GP, Iqbal K, Bucht G, Winblad B, Wisniewski HM, Grundke-Iqbal I. Alzheimer's disease: paired helical filament immunoreactivity in cerebrospinal fluid. Acta Neuropathol 1991;82:6–12.

79. Winderlov E, Brane G, Ekman R, Kihlgren M, Norberg A, Karlsson I. Elevated CSF somatostatin concentrations in demented patients parallel improved psychomotor functions induced by integrity-promoting care. Acta Psychiatr Scand 1989;79:41–47.

80. Wolozin B, Bacic M, Merrill MJ. Differential expression of carboxyl-terminal derivatives of amyloid precursor protein among call lines. J Neurosci Res 1992;33:163–169.

81. Wolozin B, Sunderland T, Zheng B, et al. Continuous culture of neuronal cells from adult human olfactory epithelium. J Mol Neurosci 1992;3:137–146.

82. Zubenko GS. Biological correlates of clinical heterogeneity in primary dementia. Neuropsychopharmacology 1992;6:77–93.

83. Zubenko GS. Endoplasmic reticulum abnormality in Alzheimer's disease: selective alteration in platelet NADH-cytochrome C reductase activity. J Geriatr Psychiatry 1989;2:3–10.

84. Zubenko GS, Cohen BM, Growdon J. Cell membrane abnormality in Alzheimer's disease. Lancet 1984;2:235.

85. Zubenko GS, Cohen BM, Reynolds CF. Platelet membrane fluidity in Alzheimer's disease and major depression. Am J Psychiatry 1987;238:539–542.

86. Zubenko GS, Huff FJ, Beyer J. Familial risk of dementia associated with a biologic subtype of Alzheimer's disease. Arch Gen Psychiatry 1988;45:889–893.

87. Zubenko GS, Malinakova I, Chojnacki B. Proliferation of internal membranes in platelets from patients with Alzheimer's disease. J Neuropathol Exp Neurol 1987;46:407–418.

88. Zubenko GS, Moossy J. Major depression in primary dementia: clinical and neuropathologic correlates. Arch Neurol 1988; 45:1182–1186.

89. Zubenko GS, Moossy J, Kopp U. Neurochemical correlates of major depression in primary dementia. Arch Neurol 1990;47:209–214.

90. Zubenko GS, Moossy J, Martinez J, et al. Neuropathologic and neurochemical correlates of psychosis in primary dementia. Arch Neurol 1991;48:619–624.

91. Zubenko GS, Rosen J, Sweet RA, Mulsant BH, Rifai AH. Impact of psychiatric hospitalization on behavioral complications of Alzheimer's disease. Am J Psychiatry 1992;149:1484–1491.

92. Zubenko GS, Wusylko M, Cohen BM. Family study of platelet membrane fluidity in Alzheimer's disease. Science 1987;238:539–542.

93. Zweig RM, Ross CA, Hedreen JC, et al. The neuropathology of aminergic nuclei in Alzheimer's disease. Ann Neurol 1988;24:233–242.